KRAS and pancreatic ductal adenocarcinoma: The EGFR-targeting approach was then evaluated in an advanced genetically engineered spontaneous mouse model of pancreatic ductal adenocarcinoma (Ptf1a+/Cre; Kras+/LSL−G12D; Tp53lox/loxP [Kras;p53]).